ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO732

Urinary CD80 and Serum suPAR as Biomarkers of Glomerular Disease Among Adults in Brazil

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Zen, Renata De cassia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Yu, Luis, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Jorge, Lectícia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Woronik, Viktoria, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil
  • Dias, Cristiane B., Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil

The objective of this study was to determine whether urinary CD80 and serum suPAR can be used for the diagnosis of MCD and FSGS, respectively, in the adult population of Brazil. We also attempted to determine whether these biomarkers assess the response to immunosuppressive treatment.


This was a prospective study in which urine and blood samples were collected, for analysis of CD80 and suPAR, respectively, only in the moment of renal biopsy, from patients undergoing to diagnostic renal biopsy. At and six months after biopsy, we analyzed serum creatinine, serum albumin, and proteinuria in order to evaluate the use of the CD80 and suPAR collected in diagnosis as markers of response to immunosuppressive treatment. In healthy controls were collected urinary CD80 and proteinuria, serum suPAR and creatinine.


The results of 70 renal biopsies were grouped, by diagnosis, as follows: FSGS (n = 18); membranous nephropathy (n = 14); MCD (n = 5); and other glomerulopathies (n = 33). There was no significant difference among the groups in terms of the urinary CD80 levels, and serum suPAR was not significantly higher in the FSGS group, as would have been expected [Table 1]. Urinary CD80 correlated positively with nephrotic syndrome, regardless of the type of glomerular disease (r= -0.5 p <0.0001). Neither biomarker correlated with proteinuria at six months after biopsy.


In adults, urinary CD80 can serve as a marker of nephrotic syndrome but is not specific for MCD, whereas serum suPAR does not appear to be useful as a diagnostic or treatment response marker.

Demographic characteristics and biomarker data at diagnosis in patients with glomerulopathies and in healthy controls
(n = 5)
(n = 18)
Membranous nephropathy
(n = 14)
(n = 10)
P value
Age (years), mean ± SD37.60 ± 1533.67 ± 13.6042.15 ± 19.6433.60 ± 6.630.003
Male sex, n (%)1 (20.0)10 (55.6)6 (42.9)3 (30.0)0.40
Serum creatinine (mg/dL), median (IQR)0.90 (0.76–1.95)2 (0.92–2.62)0.65 (0.50–1.17)1.11 (0.98–1.18)0.086
Protein-to-creatinine ratio (g/g), median (IQR)3.10 (1.04–3.46)4.05 (1.87–5.44)4.42 (2.38–7.14)0.003 (0–0.22)< 0.0001
Serum albumin (g/dL), mean ± SD2.08 ± 0.992.06 ± 0.872.25 ± 0.54-0.10
CD80 (ng/g creatinine), median (IQR)104 (19.70–369.60)63.15 (30.50–244.60)76.80 (31.22–402.20)24.70 (15.10–41.40)0.15
suPAR (pg/mL), median (IQR)3266 (2887–4225)3887 (2359–4620)3091 (2018–3711)1336 (1033–1586)0.0001*

FSGS, focal segmental glomerulosclerosis; IQR, interquartile range; MCD, minimal change disease; SD, standard deviation; suPAR, soluble urokinase plasminogen activator receptor. *FSGS vs. control.